INTRODUCTION {#s1}
============

The peroxisome proliferator-activated receptor (PPAR) nuclear receptor subfamily regulates a number of metabolic processes, including fatty acid β-oxidation, glucose utilization, cholesterol transport, energy balance and adipocyte differentiation \[[@R1]-[@R4]\]. PPARs also play important roles in modulating inflammation, proliferation, angiogenesis and neoplasia \[[@R5]-[@R8]\]. PPARs function as heterodimeric partners with RXR, and require high-affinity binding of PPAR isotype-specific ligands to engage transcription. Of the three subtypes, PPARγ is the major species expressed in the mammary gland and in primary and metastatic breast cancer and breast cancer cell lines \[[@R5]\].

PPARγ and PPARδ modulate cell fate in the mammary gland \[[@R6], [@R9], [@R10]\], suggesting that PPAR agonists or antagonists may have the potential to regulate differentiation and hence tumor progression. PPARγ agonists are potent chemopreventive agents in mammary carcinogenesis \[[@R11]\], which is consistent with the enhancement of mammary tumorigenesis by PPARγ heterozygosity \[[@R12]\]. In a large percentage of follicular thyroid cancers, PPARγ exists as the dominant-negative fusion protein, Pax8-PPARγ, associated with the t(2;3)(q13;p25) translocation \[[@R13]\]. Pax8PPARγ potently blocks PPARγ function \[[@R13], [@R14]\], rather than merely serving as a low affinity receptor that can be activated at high ligand concentrations \[[@R15]\]. Importantly, the irreversible PPARγ 'suicide' inhibitor, GW9662 \[[@R16]\], mimics the growth promoting effects of Pax8PPARγ in thyroid cells \[[@R17]\], suggesting that selective pharmacological manipulation of PPARγ is feasible.

Although many studies have addressed the interactions between different nuclear receptor subfamilies, an area of relevance to breast cancer is the inhibitory effect of PPARγ on ERα (ER) promoter activation through its interaction with ER response elements \[[@R18]\]. Conversely, ER may bind to PPARγ response elements (PPREs) to inhibit PPAR-dependent transcription \[[@R19]\]. The ER and PPARγ pathways produce opposite effects on PI3K/AKT signaling, accounting in part, for the divergent responses produced by their cognate ligands in estrogen-dependent human breast cancer cells \[[@R19]\]. These findings suggest that suppression of PPARγ may upregulate ER expression in tumors to allow the implementation of anti-estrogen therapy. As a proof of principle, this was demonstrated by the effectiveness of the ER antagonist, fulvestrant, in preventing mammary tumorigenesis in MMTV-Pax8PPARγ mice, in which tumors normally present with a more aggressive progenitor cell phenotype \[[@R10]\]. Therefore, from a chemoprevention perspective, it would be important to be able to mimic the MMTV-Pax8PPARγ transgene pharmacologically by administering a PPARγ antagonist to increase the percentage of ER^+^ tumors and render them amenable to anti-estrogen therapy. This approach would be dependent on whether a PPAR antagonist could be developed with favorable specificity and pharmacokinetic properties to achieve selective and sustained inhibition of PPARγ. Examples of PPARγ antagonists are the suicide inhibitors, GW9662 (2-chloro-5-nitro-*N*-phenylbenzamide) \[[@R16]\], 2-bromo-5-nitro-*N*-phenylbenzamide \[[@R20]\] and the structurally similar T0070907 \[[@R21]\], as well as the partial PPARγ agonists, GW0072 \[[@R22]\] and L-764406 \[[@R23]\]. Although, GW9662 and T0070907 have also been reported to produce off-target effects *in vitro* \[[@R24]-[@R26]\], their *in vivo* selectivity has yet to be demonstrated. In this report, we show that GW9662 when administered continuously in the diet beginning at the onset of mammary carcinogenesis induces ER-responsive tumors susceptible to fulvestrant therapy. Furthermore, GW9662 inhibited a PPARγ-dependent metabolic gene expression signature, including PPARγ itself. These results are the first to demonstrate that GW9662 is at least in part PPARγ-selective, and can induce sensitivity to anti-estrogen therapy.

RESULTS {#s2}
=======

GW9662 induces sensitivity to antiestrogen therapy {#s2_1}
--------------------------------------------------

To evaluate the chemopreventive effect of GW9662 on mammary tumor development, carcinogenesis was induced in FVB mice by progestin and DMBA treatment. Animals were maintained on either a control diet or a diet supplemented with 0.1% GW9662 beginning one day after the last dose of DMBA, and both groups were administered either vehicle or 250 mg/kg fulvestrant by subcutaneous injection every other week (Figure [1](#F1){ref-type="fig"}). Animals maintained on GW9662 alone exhibited a modest reduction in survival (Figure [1A](#F1){ref-type="fig"}) similar to what was observed previously in MMTV-Pax8PPARγ transgenic mice \[[@R10]\], but not a reduction in the total number of tumors (Figure [1B](#F1){ref-type="fig"}). While no significant difference in survival was noted for fulvestrant-treated control mice, a marked increase in survival (Figure [1A](#F1){ref-type="fig"}) and a reduction in tumor number (Figure [1B](#F1){ref-type="fig"}) were observed in animals maintained on GW9662 and treated with fulvestrant. Consistent with these findings was an increase in ER expression in tumors from GW9662-treated mice in comparison to animals maintained on the control diet as determined by immunohistochemical (Figure [2A](#F2){ref-type="fig"}) and western analyses (Figure [2B](#F2){ref-type="fig"}). Increased ER, as well as PR expression, was accompanied by an increase in Esr1 and Pgr mRNA levels (Figure [3A](#F3){ref-type="fig"}). GW9662 treatment also resulted in a reduction of PPARγ protein (Figure [2B](#F2){ref-type="fig"}) and mRNA (Figure [3A](#F3){ref-type="fig"}). Histological evaluation of the tumors indicated that GW9662, but not fulvestrant, produced a significant increase in the percentage of adenocarcinomas (P=0.0333) ([Table S1](#SD1){ref-type="supplementary-material"}).

![GW9662 enhances the sensitivity of mammary tumors to fulvestrant\
(A) Survival curves of mice administered a control diet, a diet supplemented with 0.1% (w/w) GW9662, 250 mg/kg fulvestrant administered s.c. every other week or the combination of the GW9662 diet and fulvestrant. GW9662 treatment alone produced a significant reduction in survival vs. control mice (*P*=0.0382), but not vs. fulvestrant treatment (*P*=0.0759); fulvestrant treatment alone did not significantly affect survival (*P*=0.7223). GW9662 and fulvestrant treatment produced a significant increase in survival vs. fulvestrant (*P*=0.0008) or GW9662 (*P*=0.0001) treatment alone. Each group contained 10 mice. Statistical significance was determined by the log rank test. (B) Tumor formation in the experimental groups indicated in (A). Neither GW9662 (*P*=0.3942) nor fulvestrant (*P*=0.3339) treatment alone significantly affected tumor number vs. control mice. GW9662 and fulvestrant treatment produced a significant reduction in tumor number vs. either fulvestrant (*P*=0.0001) or GW9662 (*P*=0.0004) treatment alone. Each group contained 10 mice. Statistical significance was determined by the two-tailed Student\'s t test.](oncotarget-03-345-g001){#F1}

![ER expression in adenocarcinomas from control and GW9662 mice\
(A) Immunohistochemical detection of ER expression. Two representative tumors from control and GW9662-treated mice are shown. ER expression was increased following GW9662 treatment. Magnification 200X. (B) Western analysis of ER and PPARγ expression. Two representative tumors from control and GW9662-treated mice are shown. ER expression was increased, and PPARγ expression reduced following GW9662 treatment. The bar graph represents quantitation of the western blot normalized to actin expression.](oncotarget-03-345-g002){#F2}

![(A) qRT-PCR analysis of gene expression in adenocarcinomas from control and GW9662-treated mice\
Gene selection was based on the data in Table [1](#T1){ref-type="table"}. (B) Heat map of changes in gene expression based on the data in [Table S2](#SD1){ref-type="supplementary-material"}.](oncotarget-03-345-g003){#F3}

Gene expression analysis {#s2_2}
------------------------

Gene microarray analysis of tumors from control and GW9662-treated animals indicated that 356 genes were differentially affected by GW9662 treatment (Figure [3B](#F3){ref-type="fig"}). Of the 303 genes downregulated by GW9662, 24% were metabolic genes, and 55% of which contain PPREs (Table [1](#T1){ref-type="table"}). In addition, there were 10 genes regulated by transcription factors Cebpa and Pouf1, which are PPAR-regulated. Overall, 67% of the metabolic genes were directly or indirectly regulated by GW9662. Gene ontology of the differentially expressed genes ([Table S1](#SD1){ref-type="supplementary-material"}) indicated that the largest percentage were associated with transport, glucose and lipid metabolism, and developmental processes (Table [2](#T2){ref-type="table"}). Pathway linkage analysis revealed that most of the genes whose expression was downregulated by GW9662 were linked directly or indirectly to PPARγ (Figure [4](#F4){ref-type="fig"}), whereas, those genes whose expression was increased by GW9662 were connected to Mapk3, Mapk8 and Akt signaling (Figure S1). Interestingly, the majority of the genes upregulated by GW9662 were associated with transcription, splicing, processing and translation of RNA ([Table S2](#SD1){ref-type="supplementary-material"}). In particular, RBM39, whose expression was increased 6.6-fold by GW9662, was recently reported to be increased in ER-dependent mammary tumors developing in caveolin-1 knockout mice \[[@R27]\].

###### Metabolic genes downregulated by GW9662

Shown are genes whose signal was \>300 in either group and were changed \[[@R3]\] 2.5-fold in GW9662-treated animals vs. control. The full list of changes in gene expression are presented in [Table S2](#SD1){ref-type="supplementary-material"}. Gene symbols in bold contain PPREs.

                                                                                                        Raw Value   
  ------------- ------------------------------------------------------------------------------ -------- ----------- ------
  **Ces3**      carboxylesterase 3                                                             −105.7   2733        25
  **Gys2**      glycogen synthase 2                                                            −74.7    558         7
  **Lep**       leptin                                                                         −74.7    1231        16
  **Aqp7**      aquaporin 7                                                                    −55.6    3523        63
  **Pnpla3**    patatin-like phospholipase domain containing 3                                 −53.9    1301        24
  Cox8b         cytochrome c oxidase, subunit VIIIb                                            −51.0    1324        26
  Cyp2e1        cytochrome P450 family 2, subfamily e, polypeptide 1                           −44.3    5209        118
  **Pck1**      phosphoenolpyruvate carboxykinase 1, cytosolic                                 −43.9    3071        70
  **Retn**      resistin                                                                       −35.7    10637       298
  **Rbp4**      retinol binding protein 4, plasma                                              −33.9    3187        94
  Lao1          L-amino acid oxidase 1                                                         −30.2    3092        103
  **Fabp3**     fatty acid binding protein 3, muscle and heart                                 −27.0    886         33
  **Cd36**      CD36 antigen                                                                   −22.5    6726        306
  **Car4**      carbonic anhydrase 4                                                           −22.3    982         44
  **Fabp4**     fatty acid binding protein 4, adipocyte                                        −21.7    7777        3543
  **Adipoq**    adiponectin, C1Q and collagen domain containing                                −21.6    10299       522
  **Adig**      adipogenin                                                                     −20.8    1676        85
  **Acsl1**     acyl-CoA synthetase long-chain family member 1                                 −18.6    3172        374
  **Lipe**      lipase, hormone sensitive                                                      −16.2    1329        82
  **Hsd11b1**   hydroxysteroid-11-beta dehydrogenase 1                                         −15.7    28.15       1.79
  **Pparg**     peroxisome proliferator activated receptor gamma                               −13.9    967         69
  Pc            pyruvate carboxylase                                                           −13.1    1588        95
  **Dgat2**     diacylglycerol O-acyltransferase 2                                             −12.4    4000        521
  Cel           carboxyl esterase lipase                                                       −12.1    955         79
  Acacb         acetyl-Coenzyme A carboxylase beta                                             −11.5    530         46
  **Acaa1b**    acetyl-Coenzyme A acyltransferase 1B                                           −10.6    696         66
  **Ephx2**     epoxide hydrolase 2, cytoplasmic                                               −10.0    1402        140
  **Lpl**       lipoprotein lipase                                                             −9.6     6823        713
  **Pgam2**     phosphoglycerate mutase 2                                                      −8.9     628         70
  **Cox6a2**    cytochrome c oxidase, subunit VI a, polypeptide 2                              −8.1     405         50
  **Fasn**      fatty acid synthase                                                            −7.3     11558       1579
  **Ptger3**    prostaglandin E receptor 3 (subtype EP3)                                       −7.1     1106        157
  Sorbs1        sorbin and SH3 domain containing 1                                             −6.5     2532        581
  Pygl          liver glycogen phosphorylase                                                   −6.4     1600        250
  **Scd1**      stearoyl-Coenzyme A desaturase 1                                               −6.4     7943        2026
  Chpt1         choline phosphotransferase 1                                                   −5.8     1658        327
  **Slc1a5**    solute carrier family 1 (neutral amino acid transporter), member 5             −5.6     2664        476
  **Acss2**     acyl-CoA synthetase short-chain family member 2                                −5.5     969         160
  **Mgll**      monoglyceride lipase                                                           −5.5     3443        632
  **Pnpla2**    patatin-like phospholipase domain containing 2                                 −5.1     4552        890
  Eno3          enolase 3, beta muscle                                                         −4.9     672         136
  **Cyp2f2**    cytochrome P450 family 2, subfamily f, polypeptide 2                           −4.9     550         112
  **Lpin1**     lipin 1                                                                        −4.8     1167        268
  Ido1          indoleamine 2,3-dioxygenase 1                                                  −4.8     406         85
  **Sod3**      superoxide dismutase 3, extracellular                                          −4.7     678         145
  Cyp4b1        cytochrome P450 family 4, subfamily b, polypeptide 1                           −4.6     1286        283
  Igf1          insulin-like growth factor 1                                                   −4.3     558         153
  Aacs          acetoacetyl-CoA synthetase                                                     −4.1     1176        320
  **Acox1**     acyl-Coenzyme A oxidase 1, palmitoyl                                           −4.1     920         225
  Xdh           xanthine dehydrogenase                                                         −3.9     1400        362
  **Gpd1**      glycerol-3-phosphate dehydrogenase 1 (soluble)                                 −3.6     1710        283
  Gpt2          glutamic pyruvate transaminase (alanine aminotransferase) 2                    −3.6     1338        438
  Gpt           glutamic pyruvic transaminase, soluble                                         −3.6     577         159
  Abca8a        ATP-binding cassette, sub-family A (ABC1), member 8a                           −3.5     1675        478
  **Me1**       malic enzyme 1, NADP(+)-dependent, cytosolic                                   −3.4     2810        900
  Aqp1          aquaporin 1                                                                    −3.4     2841        848
  Retsat        retinol saturase (all trans retinol 13,14 reductase)                           −3.3     488         146
  **Slc27a1**   solute carrier family 27 (fatty acid transporter), member 1                    −3.2     522         163
  **Lipa**      lysosomal acid lipase A                                                        −3.2     374         117
  Fads3         fatty acid desaturase 3                                                        −3.2     1545        485
  **Alox12e**   arachidonate lipoxygenase, epidermal                                           −3.1     818         262
  **Elovl6**    ELOVL family member 6, elongation of long chain fatty acids (yeast)            −3.1     1088        320
  Gpam          glycerol-3-phosphate acyltransferase, mitochondrial                            −3.0     2818        947
  Nr1h3         nuclear receptor subfamily 1, group H, member 3 (LXR)                          −3.0     1137        379
  Acly          ATP citrate lyase                                                              −2.9     993         343
  Pik3r1        phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)   −2.9     558         192
  Rbp7          retinol binding protein 7, cellular                                            −2.9     1212        418
  **Slc2a4**    solute carrier family 2 (faciltated glucose transporter), member 4             −3.2     522         163
  **Crat**      carnitine acetyltransferase                                                    −2.8     537         191
  **Slc2a4**    solute carrier family 2 (facilitated glucose transporter), member 4            −2.8     1021        364
  Sord          sorbitol dehydrogenase                                                         −2.8     700         250
  Ehhadh        enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase             −2.7     341         126
  Hk2           hexokinase 2                                                                   −2.7     1447        534
  Lpgat1        lysophosphatidylglycerol acyltransferase 1                                     −2.7     399         150
  Gbe1          glucan (1,4-alpha-)branching enzyme                                            −2.7     723         267
  Apod          apolipoprotein D                                                               −2.6     4011        1526
  Gatm          glycine amidinotransferase (L-arginine:glycine amidinotransferase              −2.6     400         152
  Ltc4s         leukotriene C4 synthase                                                        −2.6     467         179
  Pfkfb1        6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1                          −2.6     320         124
  Plin2         perilipin 2                                                                    −2.5     6773        2671
  **Cebpa**     CCAAT/enhancer binding protein (C/EBP), alpha                                  −2.5     1819        734
  **Dgat1**     diacylglycerol O-acyltransferase 1                                             −2.5     1065        425
  Ptgs1         prostaglandin-endoperoxide synthase 1                                          −2.5     362         145

###### Gene ontology of differentially expressed genes affected by GW9662

Shown are enrichment data with P\<0.05 by Fisher\'s Exact test.

  Name                                               Total Entities   Overlap   Overlapping Entities                                                                                                                  p-value
  -------------------------------------------------- ---------------- --------- ------------------------------------------------------------------------------------------------------------------------------------- ----------
  [**DOWNREGULATED:**]{.ul}                                                                                                                                                                                           
  lipid metabolism                                   342              23        CHPT1,CD36,LEP,LPL,LIPE,APOD,NR1H3,SLC27A1,LIPA,ACSL1,HSD11B1,DGAT2,CRAT,ACLY,LPIN1,ACOX1,EHHADH,PNPLA2,PCK1,PNPLA3,MGLL,AACS,FADS3   1.92E-26
  metabolism                                         858              21        LPGAT1,FASN,LIPE,ACACB,SLC27A1,EPHX2,ACSL1,GPAM,HSD11B1,ME1,PC,ACLY,PFKFB1,ACOX1,EHHADH,PNPLA2,GPD1,PNPLA3,ACSS2,PGAM2,AACS           3.71E-15
  transport                                          1807             15        AQP1,CD36,APOD,SLC2A4,SLC27A1,FABP4,FABP3,CRAT,SORBS1,SLC1A5,AQP7,RBP4,CRABP1,RBP7,FADS3                                              6.01E-05
  oxidation reduction                                702              14        CYP2E1,PTGS1,SOD3,XDH,FASN,HSD11B1,ME1,ACOX1,EHHADH,GPD1,CYP4B1,SORD,RETSAT,FADS3                                                     3.58E-09
  fatty acid metabolism                              110              12        CD36,PPARG,SLC27A1,LIPA,FABP4,ACSL1,GPAM,FABP3,CRAT,ACOX1,EHHADH,AACS                                                                 1.21E-16
  response to drug                                   295              10        ADIPOQ,PPARG,LIPE,ACACB,FABP4,ACSL1,AQP7,SORD,ENO3,AACS                                                                               5.40E-09
  response to insulin                                37               10        LEP,RETN,PIK3R1,PFKFB1,PCK1,RBP4,PPARG,SORBS1,LPIN1,NRIH3                                                                             5.81E-10
  fat cell differentiation                           29               9         ADIG,CEBPA,ADIPOQ,PPARG,SLC2A4,FABP4,IGF1,AACS,RETN                                                                                   1.21E-10
  lipid biosynthesis                                 115              8         PTGS1,FASN,DGAT2,PC,ACLY,ELOVL6,ACSS2,FADS3                                                                                           7.24E-10
  gluconeogenesis                                    33               7         GPT,PC,PFKFB1,GPD1,PCK1,RBP4,PGAM2                                                                                                    2.60E-12
  generation of precursor metabolites & energy       63               7         CEBPA,ADIPOQ,GYS2,ACOX1,AQP7,GBE1,COX6A2                                                                                              3.17E-10
  response to glucocorticoids                        95               6         CEBPA,ADIPOQ,IGF1,FABP4,PIK3R1,PFKFB1                                                                                                 1.93E-07
  response to nutrients                              117              6         CEBPA,ADIPOQ,PPARG,ACSL1,GATM,AACS                                                                                                    6.62E-07
  lipid catabolism                                   113              6         CEL,LPL,LIPE,LIPA,PNPLA2,PNPLA3                                                                                                       5.40E-07
  glucose homeostasis                                50               6         ADIPOQ,PPARG,SLC2A4,PCK1,RBP4,PYGL                                                                                                    3.87E-09
  spermatogenesis                                    353              5         ADIG,ACOX1,AQP7,RBP4,PGAM2                                                                                                            2.38E-03
  carbohydrate metabolism                            296              5         SLC2A4,ME1,GPD1,PYGL,GBE1                                                                                                             1.10E-03
  fatty acid biosynthesis                            78               5         PTGS1,FASN,ACACB,ELOVL6,FADS3                                                                                                         1.98E-06
  triglyceride biosynthesis                          11               5         LPL,GPAM,DGAT1,DGAT2,PNPLA3                                                                                                           4.97E-11
  glucose metabolism                                 115              5         ADIPOQ,LEP,HK2,PIK3R1,SORD                                                                                                            1.33E-05
  inflammatory response                              293              4         PPARG,LIPA,EPHX2,MGLL                                                                                                                 7.45E-03
  lung development                                   106              4         CEBPA,LIPA,HSD11B1,RBP4                                                                                                               1.78E-04
  organ regeneration                                 49               4         CEBPA,PPARG,LPIN1,PFKFB1                                                                                                              8.49E-06
  triglyceride catabolism                            13               4         LPL,LIPE,PNPLA2,PNPLA3                                                                                                                3.08E-08
  fatty acid beta-oxidation                          32               4         ADIPOQ,FABP3,ACOX1,EHHADH                                                                                                             1.49E-06
  glycolysis                                         68               4         HK2,PFKFB1,ENO3,PGAM2                                                                                                                 3.14E-05
  regulation of transcription                        159              4         CEBPA,NR1H3,FABP4,PPARG                                                                                                               8.53E-03
  response to ethanol                                83               3         ADIPOQ,RBP4,AACS                                                                                                                      1.37E-03
  long-chain fatty acid transport                    12               3         CD36,PPARG,FABP3                                                                                                                      3.76E-06
  aging                                              101              3         PTGS1,PIK3R1,ENO3                                                                                                                     2.41E-03
  fatty acid oxidation                               18               3         CD36,ADIPOQ,PPARG                                                                                                                     1.38E-05
  glycogen metabolism                                41               3         GYS2,PYGL,GBE1                                                                                                                        1.72E-04
  phospholipid biosynthesis                          49               3         LPGAT1,CHPT1,GPAM                                                                                                                     2.94E-04
  regulation of cell proliferation                   135              3         PTGS1,CEBPA,IGF1                                                                                                                      5.44E-03
  negative regulation of foam cell differentiation   10               3         ADIPOQ,PPARG,NR1H3                                                                                                                    2.06E-06
  [**UPREGULATED:**]{.ul}                                                                                                                                                                                             
  regulation of transcription                        2501             9         ZBTB16,MAPK8,RHOX5,BRWD1,ESRRB,RBM39,TARDBP,NFIB,THRAP3                                                                               2.24E-02
  RNA splicing                                       238              5         HNRNPA1,PABPC1,RBM39,TARDBP,RBMX                                                                                                      2.13E-05
  mRNA processing                                    277              5         PABPN1,HNRNPA1,PABPC1,RBM39,TARDBP                                                                                                    4.40E-05
  cell proliferation                                 324              4         PTHLH,EREG,ZBTB16,NFIB                                                                                                                1.13E-03
  central nervous system development                 140              3         ZBTB16,PCP4,NPTX1                                                                                                                     1.04E-03
  translational elongation                           161              3         RPS25,RPS24,RPL41                                                                                                                     1.55E-03
  cell-cell signaling                                275              3         CALCA,PTHLH,EREG                                                                                                                      6.96E-03
  apoptosis                                          550              3         ZBTB16,SLC5A8,NISCH                                                                                                                   4.29E-02

![GW9662 signaling pathways in tumors from control and GW9662-treated animals\
Pathways are based on the expression of genes that were reduced ≥2.5-fold by GW9662 in [Table S1](#SD1){ref-type="supplementary-material"}. Metabolic signaling pathways associated with genes that were downregulated by GW9662.](oncotarget-03-345-g004){#F4}

DISCUSSION {#s3}
==========

The present study was designed to determine if pharmacological inhibition of PPARγ could sensitize mammary tumor growth to antiestrogen therapy. This concept was based on our previous finding that induction of mammary carcinogenesis in transgenic mice expressing the dominant-negative Pax8PPARγ fusion protein resulted in increased ER expression and responsiveness to the ER antagonist, fulvestrant \[[@R10]\]. MMTV-Pax8PPARγ transgenic mice represent a rare mouse model in which the mammary gland exhibits a progenitor cell phenotype that results in the preferential development of ER^+^ rather than ER^−^ tumors of mixed lineage following progestin/DMBA treatment \[[@R10], [@R28]\]. A similar mammary tumor phenotype developed in caveolin-1 knockout mice that was also associated with the induction of several stem/progenitor cell markers, including RBM39 \[[@R27]\], as found in the present study. RBM39 functions primarily in RNA splicing and may also be a putative partner of the co-activator Ncoa6/PRIP \[[@R29]\]. Thus, one unexpected finding was that GW9662 upregulated a number of genes associated with transcription, processing, splicing and translation that likely contribute to the diversity of the proteome \[[@R30]\].

GW9662 is an irreversible PPARγ antagonist \[[@R16]\], although *in vitro* cell studies have also reported off-target effects \[[@R24]-[@R26]\]. However, there are no *in vivo* studies that have established whether GW9662 is PPARγ-selective. In one instance, GW9662 was shown to reduce high fat diet-induced obesity in rats when administered in the diet at a concentration of 0.1% \[[@R31]\], which was identical to the GW9662 diet used in our study. GW9662 was also shown to block the anti-inflammatory effects of the PPARγ agonist, rosiglitazone, in endotoxin-induced acute lung injury after intravenous administration \[[@R32]\]. Based on gene array profiling, we found that GW9662 elicited PPARγ specificity based on its direct and indirect inhibitory effects on the expression of metabolic genes known to be under the control of PPARs.

An important caveat to the use of GW9662 is its ability to induce a modest acceleration of tumorigenesis when administered orally at the onset of carcinogenesis. We also observed a similar effect in MMTV-Pax8PPARγ mice following progestin/DMBA mammary carcinogenesis \[[@R10]\]. While this has not been reported previously, the ability of GW9662 to *inhibit* cell growth *in vitro* similarly to PPARγ agonists \[[@R24], [@R33], [@R34]\] suggests the presence of "off-target" effects. The increase in tumorigenesis observed with GW9662 and the dominant-negative Pax8PPARγ transgene suggests that partial antagonists rather than full antagonists or drugs with greater specificity may be a useful approach for further studies. Clearly, additional pharmacokinetic and pharmacodynamic studies *in vivo* are needed to establish the bioavailability and metabolic effects of GW9662. Overall, the positive aspect of inhibiting PPARγ was its ability to sensitize tumors to the ER antagonist fulvestrant, suggesting the potential for such an approach for hormone-insensitive malignancies.

MATERIALS AND METHODS {#s4}
=====================

Animal model {#s4_1}
------------

FVB wild-type (WT) mice were obtained from Taconic Farms, Germantown, N.Y. All animal studies were conducted under protocols approved by the Georgetown University Animal Care and Use Committee.

Mammary carcinogenesis {#s4_2}
----------------------

Five week-old WT mice were treated with medroxyprogesterone acetate and DMBA as previously described \[[@R9], [@R28]\]. Briefly, mice were injected s.c. with 15 mg medroxyprogesterone acetate suspension (Depo-Provera?), and after seven days were administered four weekly doses of 1 mg DMBA/0.1 ml cottonseed oil by gavage. One day after the last dose of DMBA, mice were divided into four groups of 10 mice each: 1) one group was maintained on standard Purina Rodent Chow 5001, 2) one group was maintained on chow supplemented with 0.1% (w/w) GW9962, 2) one group was maintained on chow supplemented with GW9662 and injected s.c. every other week with 250 mg/kg fulvestrant (Faslodex^®^) and 4) one group was injected with 250 mg/kg fulvestrant every other week. GW9662 was provided by the Chemoprevention Branch, NCI. The histopathology of the resulting tumors is presented in [Table S1](#SD1){ref-type="supplementary-material"}.

Antibodies {#s4_3}
----------

The source of antibodies, their dilution and use were the following: rabbit anti-ERα (sc-542, Santa Cruz Biotechnology, 1:200 for IHC, 1:1,000 for western); rabbit anti-PgR (sc-538, Santa Cruz Biotechnology, 1:200 for IHC, 1:1,000 for western).

Immunohistochemistry {#s4_4}
--------------------

IHC analysis was carried out as previously described \[[@R9], [@R10], [@R28]\].

Western Blotting {#s4_5}
----------------

Western blotting was carried out as previously described \[[@R10]\]. Briefly, tissue was frozen in liquid nitrogen and pulverized in a mortar and pestle, and mixed with lysis buffer containing: 0.1% SDS, 0.5% NP-40, phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, 50 mM sodium fluoride, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, and protease inhibitor cocktail (Roche Diagnostics). Following incubation on ice for 30 min, lysates were cleared by centrifugation for 15 min at 13,000 x g at 4°C. Protein concentrations were determined by the Coomassie Plus Protein Assay (Pierce), and 50 μg of lysate was separated in a 4-12% NuPAGE Bis-Tris gel (Invitrogen). After wet transfer, membranes were blocked for 1 hr at room temperature in TBS (pH 7.4) containing 5% non-fat dry milk and 0.1% Tween 20. Primary antibody was incubated overnight at 4°C, and secondary antibody was incubated for 1 hr at room temperature. Proteins were visualized with either SuperSignal West Pico or SuperSignal West Dura (Pierce).

Gene Microarray Analysis {#s4_6}
------------------------

Total RNA was extracted using an RNeasy Mini Kit (Qiagen) following the manufacturer\'s protocol as previously described \[[@R10], [@R35]\]. cRNA was synthesized using the Affymetrix (Santa Clara, CA) protocol with minor modifications as described \[[@R28]\]. Biotin-labeled cRNA was fragmented for 35 min at 94°C and hybridized overnight to an Affymetrix mouse 430A 2.0 GeneChip^®^ representing approximately 22,000 annotated mouse genes by the Genomics and Epigenomics Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University. Hybridization signals were detected with an Agilent Gene Array scanner, and grid alignment and raw data generation performed with Affymetrix GeneChip^®^ Operating software 1.1. Changes in gene expression with a signal ≥300 (log2 ≥8.1) and ≥3-fold change \[[@R9], [@R35], [@R36]\] were clustered hierarchically with CIMiner software (National Cancer Institute, NIH). Array data are presented in [Table S2](#SD1){ref-type="supplementary-material"}, and complete data files were deposited in the GEO database under accession no. GSE33762.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#s4_7}
----------------------------------------------------------

Total RNA was extracted using the RNAeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer\'s protocol as previously described \[[@R10], [@R35]\]. One μg of RNA was reverse transcribed in a total volume of 20 μl using the Cloned AMV First-Strand cDNA Synthesis kit (Invitrogen). PCR was performed in triplicate in an ABI 7900 instrument (Applied Biosystems, Foster City, CA) using SYBRGreen detection (Applied Biosystems, Foster City, CA) according to the manufacturer\'s protocol. qRT-PCR primers were designed using the primer design tool at <http://www.idtdna.com/Scitools/Applications/RealTimePCR/>. Efficiencies of all primer sets ([Table S1](#SD1){ref-type="supplementary-material"}) were validated using a standard curve of five serial cDNA dilutions in water in duplicate. Primers were acceptable if the deviation from the slope of the standard curve was \<0.3, and if the melting curve showed only one product. The expression of each target gene was normalized to the expression of GAPDH, and the relative quantification method was applied using SDS2.3 software (Applied Biosystems, Foster City, CA). Primers are listed in [Table S3](#SD1){ref-type="supplementary-material"}.

Statistical Analysis {#s4_8}
--------------------

Survival curves were analyzed by Pearson\'s log rank test and cumulative tumor formation by Student\'s two-tailed t test at a significance level of *P*≤0.05.
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